Virios Therapeutics Inc. (NASDAQ:VIRI) finished Thursday with a subtraction of -$0.49 to close at $1.08, a downside of -31.21 percent. An average of 1,192,120 shares of common stock have been traded in the last five days. There was a fall of -$0.6900 in the past week, and it reached a new high 3 times over the past 12 months. The last 20 days have seen an average of 816,105 shares traded, while the 50-day average volume stands at 738,938.
VIRI stock has decreased by -43.46% in the last month. The company shares reached their 1-month lowest point of $0.9000 on 08/10/23. With the stock rallying to its 52-week high on 07/14/23, shares of the company touched a low of $0.22 and a high of $9.11 in 52 weeks. It has reached a new high 21 times so far this year and achieved 357.63% or $0.8440 in price. In spite of this, the price is down -88.15% from the 52-week high.
Top 5 AI Stocks to Buy for 2023
The artificial intelligence (AI) revolution is already here. And it's about to change everything we know about everything.
According to Grand View Research, the global AI boom could grow from about $137 billion in 2022 to more than $1.81 trillion by 2030. And investors like you always want to get in on the hottest stocks of tomorrow. Here are five of the best ways to profit from the AI boom.
Click Here to Download the FREE Report.
Sponsored
Insider Transactions
VIRI stock investors should be aware that Virios Therapeutics Inc. (VIRI) stock had its last reported insider trading activity 246 days ago on Dec 08.
Valuation Metrics
Virios Therapeutics Inc. (VIRI) stock’s beta is 1.89. Other valuation ratios to consider include the price-to-book (PB) ratio at 3.27.
Financial Health
The quick ratio of Virios Therapeutics Inc. for the three months ended March 30 was 11.90, and the current ratio was 11.90, indicating that the company is able to meet its debt obligations. Further, the company has a long term debt to equity ratio of 0.00 and a total debt to equity ratio of 0.00 for the quarter ending March 30.
For investors, determining the potential profitability of the investment also depends on the performance of the company’s management. In the past 12 months, Virios Therapeutics Inc.’s return on assets was -112.70%.
Earnings Surprise
The company posted a net income of $4.28 million in the quarter, while revenues of -$4.28 million were grew 100.0%. The analyst consensus anticipated Virios Therapeutics Inc.’s latest quarter earnings to come in at -$0.2 per share, but it turned out to be -$0.08, a 60.00% surprise. At the end of the quarter ending March 30, Virios Therapeutics Inc.’s stock balance sheet showed total liabilities of 0.55 million. Shareholders own equity worth $18.33 million.
Technical Picture
From a technical analysis perspective, let’s take a brief look at Virios Therapeutics Inc. (VIRI) price momentum. RSI 9-day as of the close on 10 August was 16.31%, suggesting the stock is oversold, with historical volatility in this time frame at 167.28%.
As of today, VIRI’s price is $1.5620 -38.98% or -$0.6900 from its 5-day moving average. VIRI is currently trading -45.73% lower than its 20-day SMA and +252.71% higher than its 100-day SMA. However, the stock’s current price level is -34.94% below the SMA50 and +250.65% above the SMA200.
The stochastic %K and %D were 10.15% and 10.11%, respectively, and the average true range (ATR) was 0.2374. With the 14-day stochastic at 13.95% and the average true range at 0.2225, the RSI (14) stands at 27.37%. The stock has reached -0.2367 on the 9-day MACD Oscillator while the 14-day reading was at -0.3826.
Analyst Ratings
The consensus rating for Virios Therapeutics Inc. (VIRI) among analysts is Hold. According to current brokerage recommendations, 0 brokerage firms advise that investors sell VIRI, while 1 suggest investors hold. There are 0 analysts who rate the stock as underweight. The stock is rated overweight by 0 analysts, while 0 others rate it as a “buy”.
What is VIRI’s price target for the next 12 months?
Analysts predict a range of price targets between $12.00 and $12.00, with a median target of $12.00. Taking a look at these predictions, the average price target given by analysts for Virios Therapeutics Inc. (VIRI) stock is $12.00.
